|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Hematologic malignancy
Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma
Do Young Kim, Jehyun Nam, Joo-seop Chung, Sang-Woo Kim, Ho-Jin Shin
Cancer Res Treat.
2022;54(1):301-313. Published online April 27, 2021 DOI:
https://doi.org/10.4143/crt.2020.1371
Web of Science 2
Crossref 4
Primary Histiocytic Sarcoma of the Central Nervous System
Hoonsub So, Sun A Kim, Dok Hyun Yoon, Shin Kwang Khang, Jihye Hwang, Chong Hyun Suh, Cheolwon Suh
Cancer Res Treat.
2015;47(2):322-328. Published online August 29, 2014 DOI:
https://doi.org/10.4143/crt.2013.163
Web of Science 16
Crossref 16
Intrapleural Chemotherapy with Cisplatin and
Cytarabine
in the Management of Malignant Pleural Effusion
Kee Won Kim, Suk Young Park, Myung Sook Kim, Seok Chan Kim, Eun Hee Lee, So Young Shin, Jong Ho Lee, Jong Bum Kweon, Kuhn Park
Cancer Res Treat.
2004;36(1):68-71. Published online February 29, 2004 DOI:
https://doi.org/10.4143/crt.2004.36.1.68
Crossref 7
Prognostic Implications of
Cytarabine
Dose in Consolidation Chemotherapy for the Patients with Acute Myelogenous Leukemia
Jung Hee Lee, Je Hwan Lee, Kyoo Hyung Lee, Hyeseung Bahng, Jin Hee Ahn, Jung Shin Lee, Sang Hee Kim, Woo Kun Kim
J Korean Cancer Assoc.
2000;32(5):954-961.
Treatment of Relapsed ro Refractory Acute leukemia with High / Intermediate - dose
Cytarabine
and Idarubicin
Seong Chul Kim, Yoo Hong Min, Hyun Jin Noh, Seung Tae Lee, Bo Yong Chung, Jee Sook Hahn, Yun Woong Ko
J Korean Cancer Assoc.
1996;28(2):301-308.
1
Journal Impact Factor 4.6